Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Middeke

Showing results (131-140 of 158) with videos related to

Pageof 16
Sort By:
Blood|August 3, 2012
Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-Jan M Middeke, Dietrich Beelen, Michael Stadler, et al.
Clinical Nutrition (Edinburgh, Scotland)|March 21, 2021
Current practice in nutrition after allogeneic hematopoietic stem cell transplantation - Results from a survey among hematopoietic stem cell transplant centersR Toenges, H Greinix, A Lawitschka, et al.
British Journal of Haematology|January 21, 2017
The TP53 Pro72Arg SNP in de novo acute myeloid leukaemia - results of two cohort studies involving 215 patients and 3759 controlsEduard Schulz, Karin Lind, Wilfried Renner, et al.
Bone Marrow Transplantation|January 12, 2016
Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantationC S Link, R Teipel, F Heidenreich, et al.
Blood Advances|January 10, 2022
Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatmentRaphael Teipel, Frank Kroschinsky, Michael Kramer, et al.
British Journal of Haematology|February 26, 2013
Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemiaBrigitte Mohr, Johannes Schetelig, Kerstin Schäfer-Eckart, et al.
Haematologica|August 31, 2019
The prevalence of extramedullary acute myeloid leukemia detected by <sup>18</sup>FDG-PET/CT: final results from the prospective PETAML trialFriedrich Stölzel, Tors Lüer, Steffen Löck, et al.
British Journal of Haematology|March 13, 2018
Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trialJohannes Schetelig, Cornelia S Link, Gernot Stuhler, et al.
Annals of Hematology|January 21, 2026
PRDM16 expression is an independent prognostic factor in AML with the double-mutant NPM1/FLT3-ITD genotypeSebastian Stasik, Jan-Niklas Eckardt, Christoph Röllig, et al.
British Journal of Haematology|March 5, 2025
The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AMLSebastian Stasik, Jan-Niklas Eckardt, Christoph Röllig, et al.
Pageof 16

Showing results (131-140 of 158) with videos related to

Sort By:
Pageof 16
Blood|August 3, 2012
Outcome of high-risk acute myeloid leukemia after allogeneic hematopoietic cell transplantation: negative impact of abnl(17p) and -5/5q-Jan M Middeke, Dietrich Beelen, Michael Stadler, et al.
Clinical Nutrition (Edinburgh, Scotland)|March 21, 2021
Current practice in nutrition after allogeneic hematopoietic stem cell transplantation - Results from a survey among hematopoietic stem cell transplant centersR Toenges, H Greinix, A Lawitschka, et al.
British Journal of Haematology|January 21, 2017
The TP53 Pro72Arg SNP in de novo acute myeloid leukaemia - results of two cohort studies involving 215 patients and 3759 controlsEduard Schulz, Karin Lind, Wilfried Renner, et al.
Bone Marrow Transplantation|January 12, 2016
Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantationC S Link, R Teipel, F Heidenreich, et al.
Blood Advances|January 10, 2022
Prevalence and variation of CHIP in patients with aggressive lymphomas undergoing CD19-directed CAR T-cell treatmentRaphael Teipel, Frank Kroschinsky, Michael Kramer, et al.
British Journal of Haematology|February 26, 2013
Impact of allogeneic haematopoietic stem cell transplantation in patients with abnl(17p) acute myeloid leukaemiaBrigitte Mohr, Johannes Schetelig, Kerstin Schäfer-Eckart, et al.
Haematologica|August 31, 2019
The prevalence of extramedullary acute myeloid leukemia detected by <sup>18</sup>FDG-PET/CT: final results from the prospective PETAML trialFriedrich Stölzel, Tors Lüer, Steffen Löck, et al.
British Journal of Haematology|March 13, 2018
Anti-CD20 immunotherapy as a bridge to tolerance, after allogeneic stem cell transplantation for patients with chronic lymphocytic leukaemia: results of the CLLX4 trialJohannes Schetelig, Cornelia S Link, Gernot Stuhler, et al.
Annals of Hematology|January 21, 2026
PRDM16 expression is an independent prognostic factor in AML with the double-mutant NPM1/FLT3-ITD genotypeSebastian Stasik, Jan-Niklas Eckardt, Christoph Röllig, et al.
British Journal of Haematology|March 5, 2025
The IKZF1 N159S mutation is associated with poor outcome and a distinct molecular profile in adult patients with AMLSebastian Stasik, Jan-Niklas Eckardt, Christoph Röllig, et al.
Pageof 16